Department of Neurology, OLVG Amsterdam, Jan Tooropstraat 164, 1061 AE, Amsterdam, The Netherlands.
Department of Epidemiology and Biostatistics Amsterdam Movement Sciences Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelenlaan 1089a, 1081 HV, Amsterdam, The Netherlands.
Trials. 2021 Jan 22;22(1):80. doi: 10.1186/s13063-020-05018-2.
Transforaminal epidural injections with steroids (TESI) are used increasingly for patients with sciatica. However, their safety, effectiveness, and cost-effectiveness are still a matter of debate. This a priori statistical analysis plan describes the methodology of the analysis for the STAR trial that assesses the (cost-)effectiveness of TESI during the acute stage of sciatica (< 8 weeks).
The STAR trial is a multicentre, randomized controlled, prospective trial (RCT) investigating the (cost-)effectiveness of TESI by making a three-group comparison among patients with acute sciatica due to a herniated lumbar disc (< 8 weeks): (1) TESI combined with levobupivacaine added to oral pain medication (intervention group 1) versus oral pain medication alone (control group), (2) intervention group 1 versus transforaminal epidural injection with levobupivacaine and saline solution added to oral pain medication (intervention group 2), and (3) intervention group 2 versus control group. Co-primary outcomes were physical functioning (Roland Morris Disability Questionnaire), pain intensity (10-point numerical rating scale), and global perceived recovery (7-point Likert scale, dichotomized into 'recovered' and 'not recovered'). For all three comparisons, we defined the following minimal clinically relevant between-group differences: two points for pain intensity (range 0-10), four points for physical functioning (range 0-24) and a 20% difference in recovery rate. Secondary outcomes are health-related quality of life (EQ-5D-5L) and patient satisfaction (7-point Likert scale) and surgery rate. We also collected resource use data to perform an economic evaluation. Analyses will be conducted by intention-to-treat with p < 0.05 (two-tailed) for all three comparisons. Effects will be estimated using mixed models by maximum likelihood. For each comparison, mean differences, or difference in proportions, between groups will be tested per time point and an overall mean difference, or difference in proportions, between groups during the complete duration of follow-up (6 months) will be estimated. In the economic evaluation, Multivariate Imputation by Chained Equations will be used to handle missing data. Cost and effect differences will be estimated using seemingly unrelated regression, and uncertainty will be estimated using bootstrapping techniques.
This statistical analysis plan provides detailed information on the intended analysis of the STAR trial, which aims to deliver evidence about the (cost-)effectiveness of TESI during the acute phase of sciatica (< 8 weeks).
Dutch National trial register NTR4457 (6 March 2014).
经皮椎间孔硬膜外类固醇注射(TESI)越来越多地用于治疗坐骨神经痛患者。然而,其安全性、有效性和成本效益仍存在争议。本预先设定的统计分析计划描述了 STAR 试验分析的方法学,该试验评估了急性坐骨神经痛(<8 周)期间 TESI 的(成本)效益。
STAR 试验是一项多中心、随机对照、前瞻性试验(RCT),通过对因腰椎间盘突出症导致的急性坐骨神经痛患者进行三组比较来评估 TESI 的(成本)效益:(1)TESI 联合口服止痛药中的左旋布比卡因(干预组 1)与单独口服止痛药(对照组);(2)干预组 1 与经皮椎间孔硬膜外注射左旋布比卡因和生理盐水联合口服止痛药(干预组 2);(3)干预组 2 与对照组。主要结局为身体功能(Roland Morris 残疾问卷)、疼痛强度(10 分数字评分量表)和整体感知恢复(7 分 Likert 量表,分为“恢复”和“未恢复”)。对于所有三种比较,我们定义了以下最小临床相关组间差异:疼痛强度差 2 分(范围 0-10),身体功能差 4 分(范围 0-24),恢复率差异 20%。次要结局为健康相关生活质量(EQ-5D-5L)和患者满意度(7 分 Likert 量表)和手术率。我们还收集了资源使用数据以进行经济评估。所有三种比较均采用意向治疗进行分析,p 值<0.05(双侧)。使用最大似然法进行混合模型估计效应。对于每个比较,将在每个时间点测试组间的平均差异或比例差异,并估计组间在整个随访期间(6 个月)的平均差异或比例差异。在经济评估中,将使用链式方程的多变量插补来处理缺失数据。将使用似无关回归估计成本和效果差异,并使用自举技术估计不确定性。
本统计分析计划提供了关于 STAR 试验预期分析的详细信息,该试验旨在提供关于 TESI 在急性坐骨神经痛(<8 周)期间的(成本)效益的证据。
荷兰国家试验登记处 NTR4457(2014 年 3 月 6 日)。